Journal Article

Susceptibility profile of 29 clinical isolates of <i>Rhodotorula</i> spp. and literature review

Alicia Gomez-Lopez, Emilia Mellado, Juan L. Rodriguez-Tudela and Manuel Cuenca-Estrella

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 55, issue 3, pages 312-316
Published in print March 2005 | ISSN: 0305-7453
Published online March 2005 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dki020
Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care

GO

Show Summary Details

Preview

Objective: In vitro susceptibility results of 29 clinical isolates of Rhodotorula spp. were analysed. In addition, the susceptibility profile of another 102 Rhodotorula isolates was reviewed.

Methods: The review included studies using antifungal susceptibility testing reference procedures or commercial methods exhibiting high correlation rates with reference procedures (Etest and Sensititre YeastOne). The 131 organisms analysed were 77 Rhodotorula mucilaginosa, 45 Rhodotorula glutinis and nine Rhodotorula spp.

Results and conclusions: Fluconazole, itraconazole and voriconazole were inactive in vitro against the majority of isolates. Amphotericin B and flucytosine exhibited good activity, being reasonable alternatives for empirical treatment. Ravuconazole was more active in vitro than other azole agents and it could be considered as an extended-spectrum triazole and maybe as a therapeutic alternative in treating infections caused by Rhodotorula species.

Keywords: Rhodotorula; susceptibility of emerging yeasts; fluconazole resistance; ravuconazole

Journal Article.  2624 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.